

WORKSHOP DETAILS

Thursday, November 3, 2005

- 9:30 – 11:00 Case Studies in Onychomycosis
- Meeting Objectives:
Debate Treatment Options from case presentations. Present group opinion through touch pad response.
- Faculty:
Dr. Aditya Gupta; Dr. Kirk Barber; Dr. Ron Vender
- 2:00 – 3:30 Shaping the Management of Psoriasis – Achieving Long-Term Control with Efalizumab
- Meeting Objectives:
The mechanism of action of efalizumab. The benefit/risk of efalizumab based on the safety and efficacy clinical data. The strategies for optimizing patient treatment with efalizumab. Patient/Treatment selection considerations based on the differences among biologicals, with regards to safety, efficacy and convenience.
- Faculty:
Yves Poulin, MD, FRCPC; Wayne Gulliver, MD, FRCPC; Kim Papp, MD, PhD, FRCPC; Neil Shear, MD, FRCPC
- 4:00 – 5:30 Taking Control over Eczema: How to Meet Patients' Needs
- Meeting Objectives:
At the end of this session the participants will be able to:
- Review and discuss the gap existing in the current treatment of eczema and the patients' needs
 - Evaluate the factors to consider in treating and managing the disease and how to provide patients with an approach to take control over their condition
 - Review data from the continuous developments and ongoing studies in the treatment of eczema.
- Faculty:
Dr. Neil Shear; Dr. Lawrence Eichenfield

Friday, November 4, 2005

- 9:30 – 11:00 New Comparative Data in the Treatment of NMSC and Insights into the Future
- Meeting Objectives:
Present advanced immunological update. Review progression of AK to SCC. Review new long-term data for imiquimod. Examine new data including an investigator initiated comparative study of topical treatments for actinic keratosis.
- Faculty:
Dr. Jason Rivers; Dr. Eggert Stockfleth; Dr. Mark Tomai
- 11:30 – 1:30 Psoriatic Arthritis and Psoriasis - A 2005 Clinical Management
- Meeting Objectives:
Interpret recent clinical trial data for anti-TNF agents used in the treatment of psoriatic arthritis and psoriasis. Identify strategies for optimizing management of patients with psoriasis and/or psoriatic arthritis in clinical practice. Discuss and share clinical experience with expert colleagues.
- Faculty:
Ian Landells, MD, FRCPC; Philip J. Mease, MD; Alexa B. Kimball, MD, MPH
- 2:00 – 3:30 AMEVIVE™: Redefining Efficacy in Psoriasis through Remission
- Psoriasis is a serious disease that has a severe impact on quality of life. Medications for psoriasis can be broken up into two groups: those that are remittive and those that are suppressive. Remittive therapies allow patients to have freedom from their disease for a period of time.
- This session will explore AMEVIVE™, the only biologic currently approved by Health Canada for the treatment of chronic plaque psoriasis. AMEVIVE™ is a remittive therapy that can be self-administered by the patient and easily incorporated into the Dermatologist's daily practice.
- Faculty:
Dr. Wayne Carey, Dr. Jennifer Cather, Dr. M. Khraishi, Dr. Charles Lynde

NOVEMBER 3RD – 4TH WORKSHOPS AND ADVISORY BOARDS
NOVEMBER 5TH PLENARY SESSIONS

MONTREAL
2005
NOVEMBER 3RD – 6TH

dermatology
U P D A T E

Sunday, November 6, 2005

8:45 – 10:45 The Changing Face of Dermatology Clinical Trials in Canada
(pre-registration required, FEE: \$150 + gst)

This year we will focus on the conduct of specialty trials in the following areas: photobiology trials, biologic trials, vaccine trials, botulinum toxin trials, as well as the general need for inter-rater reliability training.

Proposed Faculty:

Dr. Robert Bissonnette; Dr. Wayne Gulliver; Dr. Chuck Lynde; Dr. Kevin Smith; Ms. Lynne Bulger; Dr. Paul Kidson